Logo image
Early Urinary Biomarker to Identify Tolerable Radioligand Therapy Dosing: A Pilot Study: TH-PO1140
Abstract   Open access   Peer reviewed

Early Urinary Biomarker to Identify Tolerable Radioligand Therapy Dosing: A Pilot Study: TH-PO1140

Casey F. Pulliam, Claudia J. Robles-Planells, Florencia Chena-Becerra, Gabriela Vasquez Martinez, Gabriel Mayoral Andrade, Michael King Schultz and Diana Zepeda-Orozco
Journal of the American Society of Nephrology, Vol.37(10S)
10/2026
DOI: 10.1681/ASN.2026s7b6a004
url
https://doi.org/10.1681/ASN.2026s7b6a004View
Published (Version of record) Open Access

Abstract

Background: [212Pb]VMT-α-NET (212Pb-VMT) is a novel peptide-based α-emitting targeted radioligand therapy (TRT) for SSTR2-positive tumors with promising clinical safety and tumor control. Nonspecific tubular TRT uptake can cause long-term kidney toxicity, limiting clinical dose escalation. Previous studies showed that 4.4 MBq of 212Pb-VMT in ARJ42 tumor-bearing immunocompromised mice yielded complete responses, 90-day survival, and good weight tolerance (Liu et al., EANM). This pilot study evaluates early tubular urinary biomarkers to predict late-onset kidney functional decline, using a dose-escalation TRT model. Methods: To identify a 212Pb-VMT dose that would induce kidney injury, male C57BL/6J mice (8-10 wks old, n=3-5) received a single IV dose of vehicle control or 212Pb-VMT (3.7 or 5.6 MBq; 38.9-55.5 Gy RBE-weighted kidney dose). Urinary biomarkers kidney injury molecule-1 (uKIM1), neutrophil gelatinase-associated lipocalin (uNGAL), and epidermal growth factor (uEGF) were measured on days 1 (D1) and 36 (D36) and normalized to urine creatinine (uCr). Functional biomarkers, blood urea nitrogen (BUN) and serum cystatin C, were assessed on D1 and D36, and transdermal GFR (tGFR) was measured on D36, prior to euthanasia. At D36, kidney tissue was analyzed for KIM1 (tKIM1) and NGAL (tNGAL) protein expression and paraffin-embedded for blinded histological scoring. Results: There were no significant differences in histological changes, tGFR, BUN, or cystatin C on D36 between treated mice and controls. At D36, tKIM1 was increased in treated mice (Veh= 12.9; 3.7 MBq= 81.7; 5.6 MBq= 118.6 pg/mg protein; p<0.05) and tNGAL only with 5.6 MBq (p<0.05) compared with controls. D1 uNGAL was elevated (Veh=85.8; 3.7 MBq= 481.9; 5.6 MBq= 642.7 ng/mg uCr; p<0.01), D1 uEGF was reduced (vehicle=5.3; 3.7 MBq=2.6; 5.6 MBq=1.9 ug/mg uCr; p<0.01) and D36 uKIM1 increased (Veh=4.8; 3.7 MBq=27.8; 5.6 MBq=54.4 ng/mg uCr; p<0.01) in treated mice compared with controls. The injected dose strongly correlated (p<0.001) with D1 uNGAL (r=0.87), D1 uEGF (r=-0.95), D36 uKIM1 (r=0.88), and D36 tKIM1 (r=0.82). D1 uNGAL (r=0.83, p=0.001) and uEGF (r=-0.79, p=0.004) also significantly correlated with D36 tKIM1 levels. Conclusion: Our findings evidence that changes in uNGAL and uEGF one day post-212Pb-VMT are associated with tubular injury detected one month after therapy, warranting further study to link these markers to late-onset functional decline.

Details

Metrics

1 Record Views
Logo image